Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SUPN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Brexanolone FDA approved Mar 2019 · Zulresso (discontinued) |
Postpartum Depression | Phase 4 · NCT05059600 | Completed |
| SPN-812 | Healthy Lactating Women | Phase 4 · NCT06259331 | Completed |
| SPN-538 | Migraine Disorders | Phase 4 · NCT04050293 | Terminated |
| SAGE-718 | Huntington's Disease | Phase 3 · NCT05655520 | Terminated |
| Molindone | Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 · NCT02691182 | Terminated |
| SAGE-547 90 μg/kg/h | Postpartum Depression | Phase 3 · NCT02942004 | Completed |
| SAGE-547 60 μg/kg/h | Postpartum Depression | Phase 3 · NCT02942004 | Completed |
| SAGE-547 | Super-Refractory Status Epilepticus | Phase 3 · NCT02477618 | Completed |
| Apomorphine | Idiopathic Parkinson's Disease | Phase 3 · NCT02339064 | Active not recruiting |
| NV-5138 | Treatment Resistant Depression | Phase 2 · NCT05066672 | Completed |
| IR Viloxazine | Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 1/2 · NCT01107496 | Completed |
| SPN-817 | Epilepsy | Phase 2 · NCT05518578 | Recruiting |
| SPN-821 2400 mg | Major Depressive Disorder (MDD) | Phase 2 · NCT07226661 | Recruiting |
| SAGE-904 | Healthy Volunteer | Phase 1 · NCT05049343 | Completed |
| Ketamine | Healthy Volunteer | Phase 1 · NCT05049343 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SUPN holds $305M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SUPN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 17,806,183 | 15.09% | 2025-12-31 |
| Millennium Management LLC | 5%+ holder (13G) | 6,343,651 | 5.37% | 2026-09-23 |
| Jack A. Khattar Chief Executive Officer, Director · +4.34M options |
Insider | 3,413,555 | 2.89% | 2026-11-02 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 3,263,309 | 2.76% | 2026-03-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 2,900,884 | 2.46% | 2026-03-31 |
| Joseph Ciaffoni Chief Executive Officer, Director |
Insider | 790,330 | 0.67% | 2026-06-22 |
| Ryan Preblick Chief Financial Officer |
Insider | 284,751 | 0.24% | 2026-06-08 |
| Christian Heidbreder Chief Scientific Officer |
Insider | 209,337 | 0.18% | 2026-07-10 |
| Charles W Iii Newhall Director |
Insider | 124,119 | 0.11% | 2026-02-24 |
| Jeffrey W Burris Chief Legal Officer |
Insider | 71,518 | 0.06% | 2026-03-03 |
| Frederick M. Hudson Director |
Insider | 60,413 | 0.05% | 2026-03-12 |
| Georges Gemayel Director · +123,818 options |
Insider | 42,009 | 0.04% | 2026-11-02 |
Share count 118,035,272 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SUPN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →